Home/Filings/4/0001209191-22-040274
4//SEC Filing

Klencke Barbara 4

Accession 0001209191-22-040274

CIK 0001290149other

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 4:43 PM ET

Size

31.0 KB

Accession

0001209191-22-040274

Insider Transaction Report

Form 4
Period: 2022-07-01
Klencke Barbara
Chief Development Officer
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-0111,3990 total
    Exercise: $72.80Exp: 2026-09-30Common Stock (11,399 underlying)
  • Disposition to Issuer

    Common Stock

    2022-07-01$55.00/sh10,000$550,0000 total
  • Disposition to Issuer

    Common Stock

    2022-07-01$55.00/sh5,000$275,0000 total(indirect: By Spouse)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01167,0910 total
    Exercise: $13.31Exp: 2030-02-25Common Stock (167,091 underlying)
  • Disposition to Issuer

    Stock Option (right to buy

    2022-07-0111,7440 total
    Exercise: $268.20Exp: 2025-06-10Common Stock (11,744 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-012,0610 total
    Exercise: $263.20Exp: 2016-03-08Common Stock (2,061 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-011,7490 total
    Exercise: $58.00Exp: 2027-03-06Common Stock (1,749 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-014,9990 total
    Exercise: $78.40Exp: 2029-03-04Common Stock (4,999 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-014,5080 total
    Exercise: $94.40Exp: 2028-03-06Common Stock (4,508 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-0149,0000 total
    Exercise: $12.15Exp: 2030-08-12Common Stock (49,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-0130,0000 total
    Exercise: $16.73Exp: 2031-03-15Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-0150,0000 total
    Exercise: $31.54Exp: 2032-03-14Common Stock (50,000 underlying)
Footnotes (12)
  • [F1]The option fully vested on June 11, 2019.
  • [F10]On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
  • [F11]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
  • [F12]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
  • [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
  • [F3]The option fully vested on January 1, 2020.
  • [F4]The option fully vested on September 30, 2019.
  • [F5]The option fully vested on January 1, 2021.
  • [F6]The option fully vested on January 1, 2022.
  • [F7]The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
  • [F8]The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F9]Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.

Issuer

Sierra Oncology, Inc.

CIK 0001290149

Entity typeother

Related Parties

1
  • filerCIK 0001647647

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:43 PM ET
Size
31.0 KB